Learn about the latest impacts that counterfeit drugs have made upon Americans at the Partnership for Safe Medicine’s Congressional Briefing entitled “Moving Beyond the Avastin Incident: The Continued Impact of Counterfeit Drugs in the United States” on March 15, 2012, NOON, Capitol Visitor Center, Room HVC-201. Last month, the U.S. Food and Drug Administration (FDA) issued a warning to healthcare professionals and patients that a counterfeit version of the cancer drug Avastin may have been purchased and used by some medical practices in the United States. Analysis showed that the fake cancer drug did not contain any of Avastin's active ingredient and instead contained substances ranging from starch and salt to solvent chemicals like acetone, which is used in paint thinner.
While this newest incident seems outrageous, there have been a number of investigations and prosecutions in the past year of counterfeit medicine distributors who have distributed counterfeit medicines for everything from heart disease medication to diabetes medication.
Moderator Joel White, on behalf of the Partnership for Safe Medicines will present “The Continued Impact of Counterfeit Drugs & the Partnership for Safe Medicine’s Call to Action.” Connie T. Jung, R. Ph., Ph.D. of the U.S. Food and Drug Administrator’s Center for Drug Evaluation and Research and Shay Reid, from the Pharmaceutical Distribution Security Alliance will speak on recent developments in counterfeit drugs within the United States.
Lieutenant Commander Jung will present “What Government Needs to Best to Protect the U.S. Supply Chain.”
Mr. Reid will present “Safeguarding U.S. Citizens from Counterfeit Drugs.” PDSA recently floated a proposal for the Pharmaceutical Traceability Enhancement Code (RxTEC) Act. The panel discussion will start at noon at the Capitol Visitor Center and lunch will be served at 1 p.m.
Please visit their website to register for this FREE luncheon briefing.
For more information, please contact Tara Goodin at 202-591-4041 or email@example.com.